(NASDAQ: ACAD) Acadia Pharmaceuticals's forecast annual revenue growth rate of 11.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Acadia Pharmaceuticals's revenue in 2025 is $929,236,000.On average, 7 Wall Street analysts forecast ACAD's revenue for 2025 to be $174,051,076,135, with the lowest ACAD revenue forecast at $169,794,605,171, and the highest ACAD revenue forecast at $181,909,099,579. On average, 6 Wall Street analysts forecast ACAD's revenue for 2026 to be $195,098,319,211, with the lowest ACAD revenue forecast at $184,947,914,684, and the highest ACAD revenue forecast at $208,657,095,233.
In 2027, ACAD is forecast to generate $215,319,925,724 in revenue, with the lowest revenue forecast at $202,264,318,781 and the highest revenue forecast at $222,282,927,187.